| Active ingredients | Dosage form | Quantity of active ingredients | Shortage status | Availability | Reason | Last updated |
| primidone | Tablet, uncoated | 250 mg | Resolved | Available | Manufacturing | 21/11/2025 |
| trandolapril | Capsule | 2 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 21/11/2025 |
| olanzapine pamoate monohydrate | Injection, powder for | 690 mg | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 21/11/2025 |
| nortriptyline | Tablet, film coated | 10 mg | Anticipated | Available | Manufacturing | 21/11/2025 |
| lamotrigine | Tablet, chewable | 50 mg | Current | Unavailable | Manufacturing | 21/11/2025 |
| pramipexole dihydrochloride monohydrate | Tablet | .125 mg | Current | Unavailable | Manufacturing | 21/11/2025 |
| pramipexole dihydrochloride monohydrate | Tablet | 1 mg | Anticipated | Available | Manufacturing | 21/11/2025 |
| ondansetron hydrochloride dihydrate | Tablet, film coated | 4.986 mg | Anticipated | Available | Manufacturing | 21/11/2025 |
| montelukast sodium | Tablet, chewable | 4.16 mg | Current | Unavailable | Manufacturing | 21/11/2025 |
| lansoprazole | Tablet, orally disintegrating | 15 mg | Current | Limited Availability | Unexpected increase in consumer demand | 21/11/2025 |
| quetiapine fumarate | Tablet, modified release | 345.39 mg | Current | Limited Availability | Manufacturing | 21/11/2025 |
| quetiapine fumarate | Tablet, modified release | 460.52 mg | Current | Limited Availability | Manufacturing | 21/11/2025 |
| quetiapine fumarate | Tablet, modified release | 345.39 mg | Current | Limited Availability | Manufacturing | 21/11/2025 |
| mesalazine | Granules, modified release | 4 g | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 21/11/2025 |
| olmesartan medoxomil~hydrochlorothiazide | Tablet | 20 mg~12.5 mg | Current | Limited Availability | Manufacturing | 21/11/2025 |
| acamprosate calcium | Tablet, enteric coated | 333 mg | Anticipated | Available | Manufacturing | 21/11/2025 |
| latanoprost | Eye Drops, solution | .05 mg/mL | Current | Limited Availability | Manufacturing | 21/11/2025 |
| latanoprost | Eye Drops, solution | .05 mg/mL | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 21/11/2025 |
| benzathine benzylpenicillin tetrahydrate | Injection, suspension | 600000 USP Unit | Current | Unavailable | Manufacturing | 21/11/2025 |
| ropinirole hydrochloride | Tablet, film coated | .285 mg | Current | Unavailable | Manufacturing | 21/11/2025 |
| paroxetine hydrochloride | Tablet, film coated | 22.22 mg | Anticipated | Available | Manufacturing | 21/11/2025 |
| lamotrigine | Tablet, chewable | 50 mg | Current | Limited Availability | Manufacturing | 21/11/2025 |
| lamotrigine | Tablet, chewable | 100 mg | Current | Unavailable | Manufacturing | 21/11/2025 |
| lamotrigine | Tablet, chewable | 200 mg | Current | Unavailable | Manufacturing | 21/11/2025 |
| lamotrigine | Tablet, chewable | 200 mg | Anticipated | Available | Manufacturing | 21/11/2025 |
| betahistine dihydrochloride | Tablet | 16 mg | Current | Limited Availability | Manufacturing | 21/11/2025 |
| ondansetron hydrochloride dihydrate | Tablet, film coated | 4.986 mg | Anticipated | Available | Manufacturing | 21/11/2025 |
| Alteplase | Diluent, not applicable | 10 mg | Current | Limited Availability | Unexpected increase in consumer demand | 21/11/2025 |
| pramipexole dihydrochloride monohydrate | Tablet, uncoated | .125 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 21/11/2025 |
| desferrioxamine mesilate | Injection, powder for | 2 g | Anticipated | Available | Manufacturing | 21/11/2025 |
| linezolid | Injection, solution | 2 mg/mL | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 21/11/2025 |
| ciprofloxacin hydrochloride | Tablet, film coated | 873.32 mg | Current | Unavailable | Manufacturing | 21/11/2025 |
| lamotrigine | Tablet, dispersible | 100 mg | Current | Limited Availability | Manufacturing | 21/11/2025 |
| rifampicin | Oral Liquid | 20 mg/mL | Anticipated | Available | Unexpected increase in consumer demand | 20/11/2025 |
| imipramine hydrochloride | Tablet, sugar coated | 10 mg | Anticipated | Available | Manufacturing | 20/11/2025 |
| lidocaine hydrochloride | Gel | 20 mg/g | Current | Limited Availability | Manufacturing | 20/11/2025 |
| benzathine benzylpenicillin tetrahydrate | Injection, suspension | 1200000 USP Unit | Current | Emergency Supply Only | Manufacturing | 20/11/2025 |
| ondansetron hydrochloride dihydrate | Injection, solution | 10 mg | Current | Limited Availability | Manufacturing | 20/11/2025 |
| galantamine hydrobromide | Capsule, modified release | 20.512 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 20/11/2025 |
| galantamine hydrobromide | Capsule, modified release | 30.768 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 20/11/2025 |
| temozolomide | Capsule, hard | 5 mg | Current | Limited Availability | Manufacturing | 20/11/2025 |
| Alteplase | Injection, powder for | 50 mg | Resolved | Available | Unexpected increase in consumer demand | 20/11/2025 |
| tobramycin | Capsule, hard | 28 mg | Current | Emergency Supply Only | Manufacturing | 20/11/2025 |
| desvenlafaxine | Tablet, modified release | 100 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 20/11/2025 |
| desvenlafaxine | Tablet, modified release | 50 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 20/11/2025 |
| entecavir | Tablet, film coated | .5 mg | Current | Unavailable | Manufacturing | 20/11/2025 |
| entecavir | Tablet, film coated | 1 mg | Current | Limited Availability | Manufacturing | 20/11/2025 |
| armodafinil | Tablet, uncoated | 250 mg | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 20/11/2025 |
| rifampicin | Capsule | 150 mg | Current | Emergency Supply Only | Manufacturing | 20/11/2025 |
| rifampicin | Capsule | 300 mg | Current | Limited Availability | Manufacturing | 20/11/2025 |
| atomoxetine hydrochloride | Capsule, hard | 20.57 mg | Anticipated | Available | Manufacturing | 20/11/2025 |
| hydroxocobalamin acetate | Injection, solution | 1.044 mg | Anticipated | Available | Unexpected increase in consumer demand | 20/11/2025 |
| doxepin hydrochloride | Capsule, hard | 11.3 mg | Current | Limited Availability | Manufacturing | 20/11/2025 |
| levodopa~carbidopa monohydrate | Tablet, uncoated | 100 mg~27 mg | Resolved | Available | Manufacturing | 20/11/2025 |
| deferasirox | Tablet, film coated | 90 mg | Current | Limited Availability | Manufacturing | 20/11/2025 |
| deferasirox | Tablet, film coated | 360 mg | Current | Unavailable | Manufacturing | 20/11/2025 |
| escitalopram oxalate | Tablet, film coated | 25.548 mg | Current | Limited Availability | Manufacturing | 20/11/2025 |
| ropivacaine hydrochloride | Injection, solution | 7.5 mg/mL | Current | Limited Availability | Manufacturing | 20/11/2025 |
| ropivacaine hydrochloride | Injection, solution | 7.5 mg/mL | Current | Unavailable | Manufacturing | 20/11/2025 |
| ropivacaine hydrochloride | Injection, solution | 2 mg/mL | Anticipated | Available | Manufacturing | 20/11/2025 |
| olanzapine | Tablet, film coated | 5 mg | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 20/11/2025 |
| dosulepin hydrochloride | Tablet, film coated | 75 mg | Current | Limited Availability | Manufacturing | 20/11/2025 |
| olanzapine | Wafer | 5 mg | Current | Unavailable | Transport / Logistic issues / Storage capacity issues | 20/11/2025 |
| risperidone | Injection, modified release | 50 mg | Current | Limited Availability | Manufacturing | 20/11/2025 |
| nizatidine | Capsule | 300 mg | Current | Limited Availability | Manufacturing | 20/11/2025 |
| perindopril erbumine~indapamide hemihydrate | Tablet, uncoated | 4 mg~1.25 mg | Discontinued | Unavailable | Commercial Changes / Commercial viability | 20/11/2025 |
| sertraline hydrochloride | Tablet, film coated | 55.96 mg | Resolved | Available | Manufacturing | 19/11/2025 |
| minoxidil | Tablet, uncoated | 10 mg | Current | Limited Availability | Manufacturing | 19/11/2025 |
| pramipexole dihydrochloride monohydrate | Tablet | .25 mg | Current | Unavailable | Manufacturing | 19/11/2025 |
| pregabalin | Capsule, hard | 25 mg | Current | Limited Availability | Manufacturing | 19/11/2025 |
| hydrochlorothiazide~olmesartan medoxomil | Tablet | 12.5 mg~40 mg | Current | Limited Availability | Manufacturing | 19/11/2025 |
| sacubitril~valsartan | Tablet, film coated | 97.2 mg~102.8 mg | Current | Unavailable | Manufacturing | 19/11/2025 |
| tetrabenazine | Tablet, uncoated | 25 mg | Current | Unavailable | Manufacturing | 19/11/2025 |
| chlorhexidine gluconate~cetrimide | Solution, irrigation | 15 mg~150 mg | Anticipated | Available | Manufacturing | 19/11/2025 |
| chlorhexidine gluconate~cetrimide | Solution, irrigation | 4.5 mg~45 mg | Anticipated | Available | Manufacturing | 19/11/2025 |
| betiatide | Injection, powder for | 1 mg | Current | Unavailable | Manufacturing | 18/11/2025 |
| phenytoin sodium | Injection, solution | 250 mg | Current | Limited Availability | Manufacturing | 18/11/2025 |
| phenytoin sodium | Injection, solution | 100 mg | Current | Unavailable | Manufacturing | 18/11/2025 |
| olanzapine | Tablet, orally disintegrating | 5 mg | Current | Unavailable | Manufacturing | 18/11/2025 |
| ropivacaine hydrochloride | Injection, solution | 2 mg/mL | Discontinued | Unavailable | Commercial Changes / Commercial viability | 18/11/2025 |
| ropivacaine hydrochloride | Injection, solution | 2 mg/mL | Discontinued | Unavailable | Commercial Changes / Commercial viability | 18/11/2025 |
| atorvastatin calcium trihydrate~amlodipine besilate | Tablet, film coated | 43.376 mg~6.94 mg | Resolved | Available | Manufacturing | 18/11/2025 |
| hydromorphone hydrochloride | Injection, solution | 10 mg/mL | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 18/11/2025 |
| Tocilizumab | Injection, solution | 162 mg | Anticipated | Available | Manufacturing | 18/11/2025 |
| phenytoin sodium | Injection, solution | 100 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 18/11/2025 |
| phenytoin sodium | Injection, solution | 250 mg | Current | Limited Availability | Manufacturing | 18/11/2025 |
| dinoprostone | Gel | .3333 mg/g | Current | Emergency Supply Only | Manufacturing | 18/11/2025 |
| dinoprostone | Gel | .6667 mg/g | Current | Emergency Supply Only | Manufacturing | 18/11/2025 |
| flecainide acetate | Injection, solution | 10 mg/mL | Current | Unavailable | Transport / Logistic issues / Storage capacity issues | 17/11/2025 |
| prazosin hydrochloride | Tablet, uncoated | 1.095 mg | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 17/11/2025 |
| prazosin hydrochloride | Tablet, uncoated | 5.476 mg | Anticipated | Available | Unexpected increase in demand due to other sponsors unable to supply | 17/11/2025 |
| tobramycin | Injection, solution | 80 mg | Anticipated | Available | Manufacturing | 17/11/2025 |
| mupirocin | Ointment | 22 mg/g | Resolved | Available | Unexpected increase in consumer demand | 17/11/2025 |
| glimepiride | Tablet, uncoated | 1 mg | Current | Unavailable | Manufacturing | 17/11/2025 |
| risperidone | Tablet, film coated | 3 mg | Current | Unavailable | Manufacturing | 17/11/2025 |
| pramipexole dihydrochloride monohydrate | Tablet | .125 mg | Current | Unavailable | Manufacturing | 17/11/2025 |
| galantamine hydrobromide | Capsule, modified release | 10.252 mg | Current | Unavailable | Manufacturing | 17/11/2025 |
| galantamine hydrobromide | Capsule, modified release | 10.252 mg | Current | Unavailable | Manufacturing | 17/11/2025 |
| galantamine hydrobromide | Capsule, modified release | 20.504 mg | Current | Unavailable | Manufacturing | 17/11/2025 |
| galantamine hydrobromide | Capsule, modified release | 20.504 mg | Current | Unavailable | Manufacturing | 17/11/2025 |
| tranexamic acid | Injection, solution | 1000 mg | Current | Unavailable | Commercial Changes / Commercial viability | 17/11/2025 |
| pramipexole dihydrochloride monohydrate | Tablet | 1 mg | Resolved | Available | Manufacturing | 17/11/2025 |
| flecainide acetate | Tablet, uncoated | 50 mg | Anticipated | Available | Manufacturing | 17/11/2025 |
| bimatoprost | Eye Drops | .3 mg/mL | Current | Unavailable | Manufacturing | 17/11/2025 |
| anastrozole | Tablet, film coated | 1 mg | Resolved | Available | Manufacturing | 17/11/2025 |
| tenofovir disoproxil maleate~efavirenz~emtricitabine | Tablet, film coated | 300 mg~600 mg~200 mg | Current | Unavailable | Manufacturing | 17/11/2025 |
| escitalopram oxalate | Tablet, film coated | 12.74 mg | Current | Unavailable | Commercial Changes / Commercial viability | 17/11/2025 |
| escitalopram oxalate | Tablet, film coated | 25.47 mg | Current | Limited Availability | Manufacturing | 17/11/2025 |
| ambrisentan | Tablet, film coated | 10 mg | Current | Limited Availability | Manufacturing | 17/11/2025 |
| risperidone | Tablet, film coated | 1 mg | Anticipated | Available | Manufacturing | 17/11/2025 |
| dimethyl fumarate | Capsule, enteric | 240 mg | Anticipated | Available | Manufacturing | 17/11/2025 |
| fingolimod hydrochloride | Capsule | 560 microgram | Current | Limited Availability | Manufacturing | 17/11/2025 |
| oseltamivir phosphate | Capsule, hard | 98.524 mg | Current | Limited Availability | Manufacturing | 17/11/2025 |
| lamotrigine | Tablet, chewable | 100 mg | Current | Unavailable | Manufacturing | 17/11/2025 |
| rivaroxaban | Tablet, film coated | 10 mg | Resolved | Available | Manufacturing | 17/11/2025 |
| rivaroxaban | Tablet, film coated | 15 mg | Current | Limited Availability | Manufacturing | 17/11/2025 |
| sitagliptin hydrochloride monohydrate~metformin hydrochloride | Tablet, modified release | 56.685 mg~1000 mg | Current | Unavailable | Manufacturing | 17/11/2025 |
| nitrofurantoin | Capsule, hard | 50 mg | Anticipated | Available | Manufacturing | 17/11/2025 |
| patisiran sodium | Injection, concentrated | 10.5 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 17/11/2025 |
| bleomycin sulfate | Injection, powder for | 15000 IU | Current | Emergency Supply Only | Manufacturing | 17/11/2025 |
| bumetanide | Tablet, uncoated | 1 mg | Resolved | Available | Manufacturing | 17/11/2025 |
| ethinylestradiol~norethisterone | Tablet, uncoated | 36 microgram~500 microgram | Current | Limited Availability | Manufacturing | 17/11/2025 |
| voriconazole | Injection, powder for | 200 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 17/11/2025 |
| galantamine hydrobromide~galantamine | Capsule, modified release | 20.51 mg~16 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 17/11/2025 |
2025年11月24日